Stay updated with breaking news from Peter Bains. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings validate clinical proof of mechanism of MTL-CEBPA as a combination therapy in solid tumor cancers Company to initiate out-licensing activities of its immuno-oncology portfolio, including
Indivior PLC Notice of Annual General Meeting Thursday, May 4, 2023 at 11.00am At the Marlborough Theatre, No. 11 Cavendish Square, London... | March 27, 2023
Please detach this portion before posting this proxy form. Attendance Card Please bring this card with you to the Meeting and present it at... | March 27, 2023
Bengaluru (Karnataka) [India], November 15 (ANI/NewsVoir): Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30, 2022. Leadership Comments Biocon Group "We reported a strong consolidated revenue growth of 23 per cent YoY for Q2FY23 at Rs. 2,384 Crore driven by 34 per cent growth in Biosimilars, 26 per cent in Research Services and 18 per cent in the Generics business. Our Gross R&D spends increased by 52 per cent YoY this quarter to Rs. 252 Crore re...
Message : Required fields ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs, announces the strengthening of its Board and Management as well as a pre-IPO funding round to advance its lead novel hybrid interferon drug candidate Alfacyte™. The appointments announced are Peter Bains as Non-Executive Chairman, Richard Morgan as a Non-Executive Director and Allan Watson as Chief Financial Officer. Dr Magnus Nicholson, Chairman of ILC Therapeutics, will become senior adviser and non-executive director on the board. T...